Artiva Biotherapeutics, Inc.(ARTV)
$3.83+0.06 (+1.59%)
ARTV
Artiva Biotherapeutics, Inc. financials statements
$3.83
At close:+0.06 (+1.59%)
Want to see ARTV full AI Analyst Report?
Artiva Biotherapeutics, Inc. (ARTV) Ratios
490 Followers
Artiva Biotherapeutics, Inc. Ratios
ARTV's free cash flow for Q3 2026 was $-29.49M. For the 2026 fiscal year, ARTV's free cash flow was decreased by $-1.04M and operating cash flow was $-28.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.61 | 15.39 | 6.53 | 4.08 | 8.41 |
| Quick Ratio | 8.61 | 15.39 | 6.53 | 4.08 | 8.41 |
| Cash Ratio | 2.04 | 3.28 | 4.38 | 4.00 | 8.34 |
| Solvency Ratio | -3.88 | -2.44 | -0.10 | -0.21 | -0.28 |
| Operating Cash Flow Ratio | -5.86 | -4.49 | -3.88 | -1.98 | -0.79 |
| Short-Term Operating Cash Flow Coverage | -25.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 91.70M | $ 165.69M | $ -187.31M | $ -169.07M | $ -96.50M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.07 | 0.16 | 0.15 | 0.01 |
| Debt-to-Equity Ratio | 0.10 | 0.08 | -0.10 | -0.14 | -0.02 |
| Debt-to-Capital Ratio | 0.09 | 0.07 | -0.12 | -0.16 | -0.02 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.12 | -0.65 | -0.95 | -1.91 |
| Debt Service Coverage Ratio | -26.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.45 | 0.59 | 0.73 | 1.11 | 0.10 |
| Net Debt to EBITDA | 0.19 | 0.46 | 1.29 | 1.42 | 2.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | -23303.98% | -91.58% | -1213.32% | -3587.66% |
| EBITDA Margin | 0.00% | -22335.46% | -84.81% | -1189.84% | -3575.27% |
| Operating Profit Margin | 0.00% | -26805.58% | -91.58% | -1213.32% | -2660.94% |
| Pretax Profit Margin | 0.00% | -23303.98% | -82.48% | -1183.03% | -3587.66% |
| Net Profit Margin | 0.00% | -23303.98% | -82.69% | -1184.10% | -3587.66% |
| Continuous Operations Profit Margin | 0.00% | -23303.98% | -82.69% | -1184.10% | -3587.66% |
| Net Income Per EBT | 100.00% | 100.00% | 100.26% | 100.09% | 100.00% |
| EBT Per EBIT | 92.56% | 86.94% | 90.07% | 97.50% | 134.83% |
| Return on Assets (ROA) | -64.05% | -27.91% | -26.35% | -43.88% | -42.27% |
| Return on Equity (ROE) | -76.26% | -31.34% | 17.09% | 41.50% | 80.83% |
| Return on Capital Employed (ROCE) | -76.88% | -34.10% | -33.02% | -55.69% | -35.37% |
| Return on Invested Capital (ROIC) | -74.94% | -33.46% | -31.79% | -53.94% | -35.27% |
| Return on Tangible Assets | -64.05% | -27.91% | -26.35% | -43.88% | -42.27% |
| Earnings Yield | -79.97% | -23.82% | -9.91% | -27.67% | -34.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 1.72 | 19.05 | 9.39 | 4.28 |
| Payables Turnover | 7.32 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.01 | 1.36 | 0.18 | 0.49 |
| Asset Turnover | 0.00 | 0.00 | 0.32 | 0.04 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.46 | 0.04 | 0.02 |
| Cash Conversion Cycle | -49.89 | 212.31 | 19.16 | 38.86 | 85.32 |
| Days of Sales Outstanding | 0.00 | 212.31 | 19.16 | 38.86 | 85.32 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 49.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 212.31 | 19.16 | 38.86 | 85.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.14 | -2.26 | -2.04 | -2.89 | -0.87 |
| Free Cash Flow Per Share | -3.25 | -2.29 | -2.18 | -3.25 | -0.97 |
| Dividend Paid and CapEx Coverage Ratio | -29.67 | -85.72 | -14.56 | -8.07 | -8.88 |
| Capital Expenditure Coverage Ratio | -29.67 | -85.72 | -14.56 | -8.07 | -8.88 |
| Operating Cash Flow Coverage Ratio | -7.01 | -3.83 | -2.80 | -2.61 | -8.79 |
| Operating Cash Flow to Sales Ratio | 0.00 | -219.25 | -1.42 | -10.31 | -7.64 |
| Free Cash Flow Yield | -75.66% | -22.67% | -18.14% | -27.07% | -8.07% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.25 | -1.94 | -10.09 | -3.61 | -2.94 |
| Price-to-Sales (P/S) Ratio | 0.00 | 978.41 | 8.34 | 42.79 | 105.39 |
| Price-to-Book (P/B) Ratio | 0.95 | 1.32 | -1.72 | -1.50 | -2.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.32 | -4.41 | -5.51 | -3.69 | -12.39 |
| Price-to-Operating Cash Flow Ratio | -1.37 | -4.46 | -5.89 | -4.15 | -13.79 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | -0.01 | 0.16 | 0.19 | -0.01 |
| Enterprise Value Multiple | -1.10 | -3.92 | -8.55 | -2.18 | -0.72 |
| Enterprise Value | 89.11M | 219.70M | 242.79M | 127.92M | 51.82M |
| EV to EBITDA | -1.10 | -3.92 | -8.55 | -2.18 | -0.72 |
| EV to Sales | 0.00 | 875.30 | 7.25 | 25.94 | 25.88 |
| EV to Free Cash Flow | -1.12 | -3.95 | -4.79 | -2.24 | -3.04 |
| EV to Operating Cash Flow | -1.16 | -3.99 | -5.12 | -2.52 | -3.39 |
| Tangible Book Value Per Share | 4.50 | 7.66 | -6.96 | -8.00 | -5.05 |
| Shareholders’ Equity Per Share | 4.50 | 7.66 | -6.96 | -8.00 | -5.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.01 | 1.44 | 0.28 | 0.11 |
| Net Income Per Share | -3.43 | -2.40 | -1.19 | -3.32 | -4.08 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.90 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 200.51 | 1.50 | 8.92 | 21.18 |
| SG&A to Revenue | 0.00 | 68.55 | 0.42 | 4.21 | 6.43 |
| Stock-Based Compensation to Revenue | 0.00 | 27.81 | 0.21 | 1.34 | 2.15 |
| Income Quality | 0.92 | 0.84 | 1.65 | 0.86 | 0.21 |
Currency in USD

